---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-020465"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2025-02-14T23:59:59+00:00"
generated_at: "2026-05-26T21:26:40.905476+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "low"
source: SEC EDGAR
---

# Aptevo reports 100% remission in Cohort 1 of RAINIER AML trial; 59% stable disease rate in ALG.APV-527 trial

## Summary
- Mipletamig RAINIER Cohort 1: 100% of patients achieved remission within 30 days, including one MRD-negative status.
- ALG.APV-527 Phase 1: 59% (10/17 evaluable) stable disease rate; breast cancer patient stable >12 months.
- Company expects multiple data readouts in 2025 and will present at ASH in Q4 2025.
- No specific financial results for FY 2024 are disclosed in the provided exhibit text.

## SEC filing metadata
- accession: 0000950170-25-020465
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2025-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: low
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000095017025020465/0000950170-25-020465-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000095017025020465/apvo-20250214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-020465
- JSON: https://secwatch.observer/filing/0000950170-25-020465.json
- Plain text: https://secwatch.observer/filing/0000950170-25-020465.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.